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Although a radiocephalic arteriovenous fistula is
still the method of first choice as vascular access for
hemodialysis, polytetrafluoroethylene (PTFE) grafts
are increasingly used as secondary access because of
failure or the impossibility to create a radiocephalic
arteriovenous fistula. This is due to the increase in
the age and number of the population undergoing
hemodialysis.1,2 Older patients have a higher number
of comorbidities like diabetes mellitus and cardiac
disease and are more likely to have vascular problems. 
The incidence of thrombotic occlusion of PTFE
arteriovenous grafts is high and leads to graft failure
rate of about 30% within the first year after implanta-
tion. Eighty percent of the thrombotic complications
are caused by stenosis, which develops at the venous
anastomosis or in the efferent vein.3-5 This stenosis
consists of intimal hyperplasia (IH), an accumulation
of medial smooth muscle cells in the intima that pro-
liferates and deposits an extracellular matrix. This
thickening of the vessel wall leads to critical stenosis,
which jeopardizes graft flow.6 Much research has
been conducted to reveal the causes of IH.
Hemodynamic factors like compliance mismatch and
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Introduction and Methods: The most frequent complication of polytetrafluoroethylene
(PTFE) arteriovenous grafts for hemodialysis is thrombotic occlusion due to stenosis
caused by intimal hyperplasia. This complication is also known for peripheral bypass
grafts. Because the use of a venous cuff at the distal anastomosis improves the patency
of peripheral bypass grafts, we considered that it might also improve the patency of
PTFE arteriovenous grafts. Therefore, a randomized multicenter trial was carried out to
study the effect of a venous cuff at the venous anastomosis of PTFE arteriovenous grafts
on the development of stenoses and the patency rates. 
Results: Of the 120 included patients, 59 were randomized for a venous cuff. The inci-
dence of thrombotic occlusion was lower in the cuff group (0.68 per patient-year) than
in the no-cuff group (0.88 per patient-year; P = .0007). However, the primary and sec-
ondary patency rates were comparable. The cuff group tended to have fewer stenoses at
the venous and arterial anastomoses when examined with duplex scan. Graft failure was
higher in patients with an initial anastomosing vein diameter smaller than 4 mm (7 of 18
[39%]) than in those with a vein diameter of 4 mm or larger (16 of 88 [18%]; P = .052).
Local edema, skin atrophy, and obesity yielded a higher risk on graft failure (23% vs 11%).
Conclusion: A venous cuff at the venous anastomosis of PTFE arteriovenous grafts for
hemodialysis reduced the incidence of thrombotic occlusions; stenosis at the venous
anastomosis was reduced. However, this did not result in a better patency rate.
Therefore, the venous cuff should not be used routinely. Initial vein diameter and local
problems (edema, obesity, or skin atrophy) appear to be the most important risk factors
for graft failure. (J Vasc Surg 2000;32:1155-63.)
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high and low shear stress trigger the release of cellu-
lar and humoral factors from the endothelial cells and
blood components.7-15 They induce vascular smooth
muscle cell proliferation, migration, and matrix
deposition, which results in IH.
Implantation of a venous patch or cuff at the dis-
tal anastomosis of prosthetic femorodistal bypass
grafts leads to a decrease in graft thrombosis and an
increased patency rate.16-19 The cuff might improve
flow hemodynamics at the graft-native vessel junc-
tion and could lead to less IH. We hypothesized that
these cuffs or patches could also have a beneficial
effect on the thrombosis and patency rate of PTFE
graft fistulas. Therefore, a prospective, randomized
study was performed, in which the incidence of
stenoses and the number of complications and paten-
cy rates were compared in patients who received
PTFE graft arteriovenous fistulas with or without a
venous cuff implantation at the venous anastomosis.
PATIENTS AND METHODS
Patients. A prospective, randomized trial was
conducted between October 1994 and June 1998 in
six hemodialysis centers. Patients who were consid-
ered for secondary access surgery or who had no
suitable vessels for primary access were included, and
all patients entered the study once. During the same
study period, 346 nonrandomized access procedures
were performed with native arteriovenous fistulas
and upper arm grafts. Patients were randomized for
a PTFE arteriovenous graft with or without a venous
cuff by means of computerized randomization.
Patient characteristics and the use of drugs were reg-
istered. The study was approved by the Ethics
Committee of the hospitals concerned, and
informed consent was obtained from each patient.
Operative procedure. Thin-walled stretch PTFE
grafts (Gore-Tex; W. L. Gore & Assoc, Flagstaff,
Ariz) with an internal diameter of 6 mm and a wall
thickness of 0.4 mm were positioned in a subcuta-
neous loop fashion in the forearm between the
brachial artery and a suitable elbow vein, after the
diameter of the vessels was measured with coronary
probes that were calibrated with 0.5-mm increments.
The minimum acceptable vein diameter for anasto-
mosing was 2 mm. The vein segment was taken from
the basilic vein in the forearm in 35 patients, from an
upper arm vein in 4 patients, and from the greater
saphenous vein in the ankle in 16 patients. In four
patients in the cuff group, no suitable vein could be
found to use as a cuff. These patients were analyzed
in the cuff group according to the intention-to-treat
principle, although we also performed an analysis
without these patients, which left 55 patients in the
cuff group. The results of both analyses were compa-
rable; therefore, we only present the results of the
whole group. The venous cuff was created according
to the technique initially described by Tyrrell and
Wolfe.20 A vein segment of 6 cm was derived from
the arm or ankle and was opened lengthwise and
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Fig 1 Primary patency rates. Number of patients is presented in the graph. When less then eight
patients entered the analysis, the graph was no longer statistically reliable.
trimmed to a 5-mm width. A 1.5-cm long incision
was made in the elbow vein, and the short side of the
cuff was anastomosed to the proximal part of the
venotomy. Subsequently, the long side of the cuff was
sutured circumferentially to both sides of the venot-
omy. Finally, the abundant vein was trimmed and
sutured to the proximal vein cuff. To enlarge the cuff
opening, we partially opened the heel of the cuff with
scissors. After vein cuff completion, the prosthesis
was anastomosed to the cuff. Arterial and venous
anastomoses were performed with running 7 × 0
polypropylene (Prolene) sutures. Prophylactic antibi-
otic therapy was given during each procedure.
Coumarin was given postoperatively to all patients in
a dosage that was sufficient for an adequate antico-
agulation (international normalized ratio > 2.5).
Follow-up. Duplex scan examination was per-
formed 3 months postoperatively. The patients were
examined while they were in the supine position by
means of B-mode imaging and Doppler scan spec-
trum measurement of the brachial artery in the upper
arm, the arterial anastomosis, the graft, the venous
anastomosis, and the efferent vein up to the subcla-
vian vein. Peak systolic velocity (PSV), end-diastolic
velocity, and diameter were measured at defined sites
and saved as video prints. Significant stenoses with a
diameter reduction of 50% (75% area reduction) or
more were diagnosed according to previously out-
lined criteria.21 Also, volume flow was measured in
the brachial artery and the PTFE prosthesis.
Fistulography of the PTFE arteriovenous grafts
was performed 3 months postoperatively. Contrast
was injected through the dialysis needle into the
graft. The graft, venous anastomosis, and outflow
tract were depicted, and visualization of the arteri-
al anastomosis and the brachial artery was obtained
with a proximal occluding cuff.22 The percentage
of diameter reduction was calculated by dividing
the diameter in the stenosis by the diameter of the
adjacent normal vessel. Only stenoses with a diam-
eter reduction of 50% or more were included for
analysis. Complications were treated according to
local customs of the hospital where the patient was.
Early and late complications were registered, and
interventional and surgical revisions were noticed.
Analysis. Statistical analysis of the clinical
patient variables was performed with the χ2 test.
The patency rates were calculated with life table
analysis and compared with the log-rank test.
Primary patency rate was defined as the percentage
of grafts that functioned well without any surgical
or catheter intervention after implantation. Primary
assisted patency was defined as the percentage of
grafts that functioned well without graft occlusion
more than 24 hours after surgery. In this definition,
grafts needing intervention for postoperative bleed-
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Table I. Patient characteristics*
No cuff Cuff P value
No. of patients 61 59
Age (y) 63 (2) 62 (2) .57
Male 29 (48%) 17 (29%) .035
Duration of kidney failure (mo) 17 (5) 24 (6) .35
Previous kidney transplantation 8 (14%) 7 (12%) .84
Previous accesses 27 (46%) 33 (57%) .23
Causes of end-stage renal disease
Glomerulosclerosis 19 (33%) 19 (34%) .84
Diabetes mellitus 12 (21%) 6 (11%) .23
Hydronephrosis, lithiasis 7 (12%) 8 (15%) .70
Polycystic kidney disease 5 (9%) 8 (15%) .32
Pharmacologic/contrast allergy 5 (9%) 4 (7%) .79
Unknown 2 (3%) 3 (5%) .60
Other 9 (15%) 7 (12%) .67
Medical history
Smoking 17 (32%) 14 (27%) .56
Diabetes mellitus 20 (35%) 12 (21%) .097
Hypertension 36 (62%) 31 (54%) .35
Ischemic cardiac disease 16 (28%) 18 (31%) .68
Peripheral vascular disease 11 (19%) 12 (21%) .82
Cerebrovascular disease 9 (16%) 11 (19%) .65
Diameter artery (mm) in the elbow 3.9 (0.13) 4.2 (0.14) .25
Diameter vein (mm) in the elbow 4.5 (0.12) 4.4 (0.16) .80
*Age, duration of kidney failure, and vascular dimensions are presented as mean (SEM). All others are presented as number of patients (%).
ing or occlusion due to postoperative hypotension
or technical failures occurring within 24 hours after
graft implantation were considered patent. Also,
grafts needing intervention for stenosis to prevent
occlusion were considered patent. Interventions for
other reasons were scored as an event. For calcula-
tion of the thrombosis-free patency, only thrombot-
ic occlusions were scored as an event. Secondary
patency was defined as the proportion of patent
grafts still in use for hemodialysis, including those
requiring elective intervention or intervention for
graft failure. Patients with a patent graft who died,
who received a transplant, or who withdrew from
hemodialysis therapy alive were censored. Clinical
risk factors were defined as a body mass index above
30, significant pitting edema, and skin atrophy that
were seen during physical examination of the
patient. End points were reached in case of irre-
versible graft failure, death, transplantation, or
transfer to continuous ambulatory peritoneal dialy-
sis treatment.
The incidence rate was defined as the number of
complications or interventions per patient-year, and
the rate was analyzed with Poisson regression analy-
sis. Risk factors, end points, duplex scan parameters,
and fistulography findings in the two groups were
compared by means of the χ2 test and correlated
with patency by means of the Pearson correlation
coefficient. Means were compared by use of the
Student t test. Differences between the groups were
considered to be statistically significant when the P
value was less than .05.
RESULTS
Patient characteristics, trial end points, paten-
cy rates, complications, and interventions. A total
of 120 patients were enrolled in the study, with 61
patients randomized for no cuff and 59 for a cuff.
Patient characteristics are summarized in Table I.
More men entered the no-cuff group (48%) than the
cuff group (29%, P = .034). Other risk factors like
age, duration of kidney failure, previous vascular
access, arterial and venous diameter, and medical his-
tory were equally distributed. Forty patients (34%)
received a graft because of failure of the radiocephal-
ic fistula, 23 (17%) because of secondary access fail-
ure, and 57 (49%) because primary creation of a
radiocephalic fistula was not possible. Total follow-up
was 84.0 patient-years (range, 7 days–3.4 years;
median, 1.4 years) for the no-cuff group and 77.5
patient-years (range, 0 days–3.6 years; median, 1.3
years) for the cuff group. Forty-nine percent of the
patients in each group had a patent graft at the end
of the study. Twenty-five patients with a patent fistu-
la died of complications of their kidney failure. Ten
patients received a kidney transplantation. In one
patient, the transplantation failed within 1 week, and
this patient remained in the study. Two patients with
a patent graft turned to continuous ambulatory peri-
toneal dialysis treatment.
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Fig 2. Secondary patency rates. Number of patients is presented in the graph. When less than eight
patients entered the analysis, the graph was no longer statistically reliable.
Life table analysis showed all patency rates to be
comparable between the two groups. There was a pri-
mary patency of 69% at 6 months, 56% at 1 year, 42%
at 18 months, and 34% at 2 years in the no-cuff group
and 62%, 43%, 30%, and 19%, respectively, in the cuff
group (P = .097, Fig 1). The primary assisted patency
was 76% at 6 months, 62% at 1 year, 52% at 18
months, and 43% at 2 years without a cuff and 71%,
60%, 53%, and 41%, respectively, with a cuff (P = .53).
The secondary patency was 86% at 6 months, 84% at
1 year, 79% at 18 months, and 79% at 2 years without
a cuff and 89%, 81%, 76%, and 65%, respectively, with
a cuff (P = .42, Fig 2). The effect of the cuff on throm-
bosis-free patency was assessed with exclusion of the
four patients who had no suitable vein to create a cuff.
The primary patency in the no-cuff group was 60% at
1 year and 42% at 2 years. In the cuff group, the pri-
mary patency was 55% at 1 year and 37% at 2 years (P
= .49). Patency rates in patients with cuffs taken either
from the forearm or upper arm basilic vein and saphe-
nous vein from the ankle were similar. 
In the overall group, 35 patients (57%) without
cuffs underwent 94 interventions, and in 36 patients
(61%) with cuffs, 92 interventions were performed
(Table II). Early occlusion was successfully treated
with thrombectomy in five patients (8%) in the no-
cuff group and in four patients in the cuff group (7%,
P = .77). Late complications were noticed in 33
patients (54%) without cuffs and in 35 patients (59%)
with cuffs (P = .56). By far the most frequent compli-
cation was thrombosis, which occurred 74 times
(0.88 per patient-year) in 28 patients in the no-cuff
group and 53 times (0.68 per patient-year, P = .0007)
in 22 patients in the cuff group. The main interven-
tion for thrombosis was surgical thrombectomy with
revision (0.43 per patient-year without cuff and 0.36
per patient-year with cuff) or without revision (0.43
per patient-year without cuff and 0.34 per patient-
year with cuff). Occasionally, fibrinolysis was per-
formed with percutaneous transluminal angioplasty
(PTA) (0.02 per patient-year without cuff) or without
PTA (0.02 per patient-year without cuff).
Stenosis was the second most frequent complica-
tion for which intervention was necessary: 12 times
(0.14 per patient-year) in 11 patients in the no-cuff
group and 17 times (0.22 per patient-year, P = .77)
in 12 patients in the cuff group. It was treated with
PTA nine times (0.11 per patient-year) in eight
patients in the no-cuff group and 13 times (0.17 per
patient-year) in 11 patients in the cuff group. In the
other cases, surgical revision was carried out because
of the extension of the stenosis. Infection was seen
once (0.01 per patient-year) in the no-cuff group
and five times (0.06 per patient-year; P = .45) in five
patients in the cuff group. The operative procedure
with a venous cuff usually took about half an hour
longer than a normal procedure; however, most
infections occurred more than 2 months after
surgery. This suggests that the infections are not due
to perioperative contamination but are caused by
repetitive puncture. In three patients in the cuff
group, explantation of the graft was necessary (0.04
per patient-year). The other grafts were salvaged
with partial excision and jump graft (0.01 per
patient-year in the no-cuff group and 0.03 per
patient-year in the cuff group). Hemorrhage
occurred once (0.01 per patient-year) in the no-cuff
group after puncture and 8 times (0.10 per patient-
year) in 6 patients in the cuff group, 3 times after
intervention and 5 times after puncture. All patients
received coumarin postoperatively, and the hemor-
rhage was not located in the cuff area. Hemorrhage
was treated with surgical closure of the bleeding site.
Pseudoaneurysms were excised twice (0.02 per
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Table II. Indications for interventions
No cuff Cuff
Events Pat Inc (py) Events Pat Inc (py)
Thrombosis 74 28 0.88 53 22 0.68*
Stenosis 12 11 0.14 17 12 0.22
Infection 1 1 0.01 5 5 0.06
Hemorrhage 1 1 0.01 8 6 0.10
Pseudoaneurysm 2 2 0.02 3 3 0.04
Ischemia 0 0 0 3 2 0.04
Venous hypertension 1 1 0.01 0 0 0
Seroma 3 2 0.04 3 1 0.04
Total events/patients 94 35† 1.12 92 36† 1.19
*P < .05 cuff group versus no-cuff group.
†The total number of patients that had complications is less than the sum because some patients had more than one complication.
patient-year) in 2 patients in the no-cuff group and
3 times (0.04 per patient-year; P = .97) in 3 patients
in the cuff group. Three interventions (0.04 per
patient-year) were performed in two patients with
ischemia of the hand. In one patient, banding was
attempted to reduce the complaints, without suc-
cess. In both patients, the graft was ligated. In one
patient, the ischemic damage was irreversible and
required arm amputation. Venous hypertension
occurred in one patient (0.01 per patient-year) in
the no-cuff group, and the graft was ligated. In each
group, three interventions (0.04 per patient-year)
were undertaken for excessive oozing of the graft,
which caused severe edema of the arm. Fibrin glue
(Tissuecol) was used three times to seal the graft,
without success. All three grafts were explanted.
Results of duplex scanning and fistulography
at 3 months. Duplex scan examination was per-
formed in 59 patients (29 without cuffs and 30 with
cuffs) 3 months postoperatively (Table III). A total
of 48 stenoses were found in the no-cuff group com-
pared to 34 stenoses in the cuff group (P = .066).
These stenoses occurred in 21 patients in both
groups. There was no difference in the distribution
of the stenoses, although the group without cuffs
tended to have more anastomotic stenoses than the
group with cuffs (14 vs 8 at the arterial anastomosis,
P = .097; 14 vs 8 at the venous anastomosis, P =
.097). Comparison of hemodynamic parameters,
measured with duplex scan examination, revealed no
difference between the two groups (Table IV). No
significant correlation was found between the vol-
ume flow in the brachial artery or prosthesis and the
primary and secondary patency. 
At 3 months, a fistulography was performed in
59 patients (30 without cuffs and 29 with cuffs).
Fewer significant stenoses (> 50%) were revealed by
fistulography than by duplex scanning. Most
stenoses were located in the venous anastomosis and
the efferent vein. No significant differences were
found in the distribution of the stenoses between the
groups without and with cuff.
Analysis of risk factors. No correlation was
found between the presence of risk factors listed in
Table I and the occurrence of graft failure. Additional
analysis was performed on the occurrence of graft
failure and the use of erythropoietin, acetylsalicylic
acid, and angiotensin-converting enzyme–inhibitors,
which showed no correlation. In 102 patients, the
presence of edema, skin atrophy, or obesity of the
arm was scored. The presence of one of these prob-
lems tended to impose a higher risk on graft failure
(11 [23%] of 47) than without local problems (graft
failure 6 [11%] of 55; P = .091). Of the 106 veins in
which the diameter was measured with coronary
probes, seven (39%) of the 18 fistulas connected to a
vein of 3.5-mm diameter or smaller occluded, where-
as only 16 (18%) of the 88 fistulas connected to a
vein of 4 mm or larger occluded (P = .052). The
diameters measured with duplex ultrasound scan at 3
months were not correlated with fistula failure.
DISCUSSION
In the current randomized study, the incidence
of thrombotic occlusions was less in the group with
a venous cuff at the venous anastomosis of PTFE
arteriovenous grafts. This was probably due to a
lower number of stenoses found with duplex scan
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Table III. Number and locations of > 50% stenoses detected with duplex (D) scan examination and fistu-
lography (X) at 3 months (n = 59) 
No cuff (n = 29) Cuff (n = 30) P value
Brachial artery (D) 2 (4%) 1 (4%) .51
Arterial anastomosis (D) 14 (29%) 8 (24%) .097
Arterial part of loop (D) 2 (4%) 2 (6%) .91
Venous part of loop (D) 2 (4%) 2 (6%) .91
Venous anastomosis (D) 14 (29%) 8 (24%) .097
Efferent vein < 2 cm (D) 9 (19%) 11 (32%) .72
Efferent vein > 2 cm (D) 5 (11%) 2 (6%) .23
Total number of stenoses (D) 48 34 .066
Total number of patients with stenoses (D) 21 (72%) 21 (70%) .66
Arterial anastomosis (X) 0 0 .98
Arterial part of loop (X) 1 (3%) 1 (3%) .98
Venous part of loop (X) 1 (3%) 1 (3%) .98
Venous anastomosis (X) 5 (17%) 3 (10%) .48
Efferent vein < 2 cm (X) 4 (13%) 8 (28%) .17
Efferent vein > 2 cm (X) 2 (7%) 6 (21%) .12
Subclavian vein (X) 2 (7%) 0 .16
examination, although the total number of patients
with stenoses was comparable. The decrease in
thrombotic occlusions did not result in a better
patency in the cuff group, because in the cuff group
fewer recurrent occlusions occurred, whereas the
total number of patients with thrombotic occlusions
was the same as in the no-cuff group. The 1-year
patency rates are comparable to the results reported
in the literature, varying from 40% to 57% for pri-
mary patency and 62% to 78% for secondary paten-
cy.3,23-29 The most frequent complication needing
intervention was thrombosis, followed by interven-
tions for stenosis that caused impaired fistula func-
tion. The cuff group had more interventions for
infections (0.06 per patient-year vs 0.01 per patient-
year in the no-cuff group), but they are still well
below the 0.21 to 0.37 per patient-year and the inci-
dence of 11% to 34% reported by others.3,24,26-29
No correlation was found between risk factors such
as age, sex, smoking, diabetes, cardiovascular dis-
ease, and cerebrovascular disease and the occurrence
of fistula failure. Erythropoietin increases the hemo-
globin value and hematocrit and may result in a
higher number of thromboses.30 However, many
studies, including this one, could not confirm
this.31-35 Acetylsalicylic acid36-38 and angiotensin-
converting enzyme–inhibitors39-41 have both been
indicated as possible inhibitors of IH. In the current
study, patients using these drugs did not have less
graft failure.
Local thickness of the arm due to edema or obe-
sity hampers palpation of the graft. Apart from the
problems this poses for graft puncture, it also
decreases the possibility to detect stenoses or even
occlusion by palpation of the graft. Atrophy of the
skin increases the risk on wound healing problems.
We found that patients with local problems had
more graft failures.
The importance of vessel diameter was already
recognized for the development and patency of
Brescia-Cimino (BC) fistulas. Wong et al42 found
that BC fistulas created with vessels with a diameter
less than 1.6 mm, which were measured with preop-
erative duplex scan examination, failed to mature.
Our study shows that the diameter of the efferent
vein is an important factor for the patency of PTFE
arteriovenous grafts, too. Of the fistulas with a diam-
eter of 3.5 mm or less, seven (39%) of 18 failed,
whereas only 16 (18%) of 88 of the fistulas with a
vein diameter of 4 mm or more failed. A smaller
efferent vein poses a higher resistance to flow, and
this could reduce the flow through the fistula.
Moreover, a large transition of diameter at the anas-
tomosis induces great flow disturbances. This would
predispose a smaller vein to a greater hyperplastic
reaction than a larger vein, compromising the flow
even more. 
PTFE is generally regarded as the material of
choice for secondary access surgery, when a BC fistula
has failed or its construction is not possible.43
However, PTFE arteriovenous grafts have significant-
ly more complications than BC fistulas.24,27,28
Thrombotic occlusion in PTFE arteriovenous grafts
occurs with an incidence of 0.54 to 0.95 per patient-
year,2,5,24,29 requiring intervention to reestablish
patency or even implantation of a new graft. The key
event in the occurrence of thrombotic complications
in PTFE arteriovenous grafts for hemodialysis is IH.6
Stenoses due to IH also develop at the distal anasto-
mosis of peripheral arterial bypass grafts and cause a
decrease of patency. In an attempt to improve patency
rates of peripheral bypass grafts, Siegman44 created a
venous cuff between the prosthesis and the native ves-
sel to facilitate the anastomosis. After Miller et al’s18
publication of improved patency rates with the use of
this venous cuff, the cuffed anastomosis was interna-
tionally accepted. The improved patency rates of the
Miller cuff were ascribed to the better transition of
elastic properties and the insertion of venous endothe-
lium, which might serve as a source for humoral fac-
tors preventing IH.45 Since then, several different
types of cuffs and patches were developed, accompa-
nied with reports of improved patencies in retrospec-
tive studies.20,46-48
In an in vitro model, the hemodynamic changes
induced by the venous cuff were examined to explain
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Table IV. Hemodynamic parameters from duplex scan examination at 3 months (n = 59)
No cuff (29) mean (SEM) Cuff (30) mean (SEM) P value
Flow brachial artery (mL/min) 1707 (95) 1520 (153) .31
Flow prosthesis (mL/min) 1623 (117) 1392 (146) .23
PSV brachial artery (m/s) 2.14 (0.24) 1.71 (0.10) .098
PSV venous anastomosis (m/s) 4.19 (0.90) 3.83 (1.27) .82
PSV efferent vein < 2 cm (m/s) 2.41 (0.32) 2.69 (0.34) .54
PSV efferent vein > 5 cm (m/s) 1.56 (0.26) 1.35 (0.17) .49
the beneficial effect of a venous cuff in the develop-
ment of IH. In the venous cuff, unidirectional vor-
tices originated with relatively high velocities. This
high velocity would exert a high shear stress on the
vessel wall, inhibiting IH.49 However, in this model,
flows were comparable to those in arterial bypass
grafts, and it is questionable whether the results can
be extrapolated to the high flow system like the arte-
riovenous fistula. On the contrary, in previous stud-
ies performed in our institute, we could prove that
initial high shear stress resulted in significantly more
stenoses.50 Also, we showed a correlation among
high shear stress, endothelial denudation of the ves-
sel wall, and IH.51 Moreover, a recent randomized
trial showed that the Miller cuff had no effect on the
patency of supragenual bypass grafts. In infragenual
bypass grafts, a better patency was obtained, but this
was ascribed to facilitation of the anastomosing tech-
nique between a stiff prosthesis and a small-caliber
crural vessel, and not to mechanical or humoral
effects of the cuff.52 In the creation of PTFE arterio-
venous loop grafts in the arm, the efferent vein in the
elbow is usually easily accessible and has a diameter
greater than 2 mm. Therefore, PTFE arteriovenous
grafts may not benefit from this technical advantage
of the cuff. Nevertheless, a recent presentation of the
results of a nonrandomized study of PTFE arteriove-
nous grafts, in which a kind of Linton PTFE patch at
the venous anastomosis was used, showed an
improved patency rate (88% after 48 months) com-
pared with 4- to 7-mm tapered grafts (66% after 36
months; P = .047).53 Also, a new type of PTFE pros-
thesis was designed with a cuffed or hooded venous
end and used to create PTFE arteriovenous grafts.
Early reports are promising, with an improved 4-
month secondary patency of 100% versus 59% for the
4- to 7-mm tapered graft. This study was not ran-
domized either, and the patency of the tapered graft
seems to be very low.54
In this prospective, randomized study, we found
that a venous cuff at the venous anastomosis of
PTFE arteriovenous grafts for hemodialysis reduces
the incidence of thrombotic occlusions through a
reduction of stenosis at the venous anastomosis.
However, this did not result in a better patency rate.
Therefore, the venous cuff should not be used rou-
tinely. Initial vein diameter and local risk factors
(edema, obesity, or skin atrophy) appear to be the
most important risk factors for graft failure.
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